# Weight-Loss Jabs Cut Sparkling Wine Sales More Than Other Alcohol

> A major study reveals that weight-loss injections like Ozempic and Wegovy cause users to drastically reduce their consumption of sparkling wine.

- Publisher: Briefzora (https://briefzora.com)
- URL: https://briefzora.com/weight-loss-jabs-cut-sparkling-wine-sales-more-than-other-alcohol
- Published: 2026-11-21T14:06:03+05:00
- Author: Briefzora Desk (https://briefzora.com/author/briefzora-desk)
- Section: Health
- Topics: The Sun Newspaper, Diet nutrition and weight loss, Exclusives, Obesity, Ozempic
- Image: https://briefzora.com/uploads/2026/11/fat-jabs-put-users-off-drinking-fizzy-wine-more-than-any-other-type-of-bqab4w.webp

## Key points

- Weight-loss jabs reduce sparkling wine purchases by 27 percent in UK households.
- Study results were presented at the Obesity Week conference in Maryland, US.
- Users of medications like Ozempic and Wegovy spent 33 per cent less on champagne and prosecco.
- Still wine consumption increased by 12 percent among households with a weight-loss drug user.

## Why it matters

Patients using weight-loss medications experience altered cravings, significantly reducing their consumption of sparkling wine and other alcoholic beverages while altering overall grocery shopping habits.

## Article

Weight-loss jabs put users off fizzy wine such as champagne and prosecco more than other types of booze, according to a major study. Doctors say the medications curb cravings for alcohol as well as carbohydrate-heavy junk food, but research shows sparkling wine is particularly shunned by individuals taking drugs such as Ozempic and Wegovy.

Analysis of the shopping habits of 19,000 UK homes by their maker Novo Nordisk found a significant drop in the amount of alcohol purchased by households with one or more users of these weight-loss treatments. The greatest fall occurred in orders for sparkling wines including French champagne, Italian prosecco, and Spanish cava.

Households using the treatments bought 27 per cent fewer bottles and spent 33 per cent less on sparkling wine compared to homes with no users of the GLP-1 drugs. Cider was the next hardest hit category, recording a 26 per cent drop by volume, followed by spirits with a 13 per cent decrease and lager with a 12 per cent decline.

Almost one in five participants in the study, representing 19 per cent of the total, stated they felt less desire to consume alcohol after starting their weight management routines. Still wine was the sole category where consumption appeared to increase, showing a 12 per cent rise across the analyzed households.

Families with a weight-loss medication user also tended to buy greater quantities of ready meals, fruit juice, water, yoghurt, and protein bars. Conversely, they reduced spending on traditional comfort items such as pasta, bread, pies, and pizza during the observation period.

Presenting the results at the Obesity Week conference in Maryland, United States, study author Timothy Arnaut of Novo Nordisk reported that spending on alcohol was strongly negatively impacted by the medications. George Godfrey, the UK medical director at the Danish pharmaceutical company, noted that managing weight involves many everyday decisions and behaviors beyond simple willpower.

Market research from Worldpanel by Numerator estimated that 8.5 per cent of UK homes currently include a user of weight-loss injections or pills. These new results add to the growing body of evidence indicating that the treatments influence broader lifestyle habits and health patterns.

## Background on GLP-1 Receptor Agonists

Weight loss injections have gained immense popularity as clinical trials and patient testimonials demonstrate their effectiveness in helping individuals shed excess body fat. Medications such as Wegovy and Mounjaro represent the leading weight loss treatments currently used across the United Kingdom. Wegovy contains the active ingredient semaglutide, which is a modified version of the type 2 diabetes medication Ozempic. Mounjaro contains tirzepatide, a newer and more potent addition to the pharmaceutical market that accounts for the majority of private prescriptions for weight management.

These medications function primarily by suppressing appetite, prompting individuals to consume smaller portions so the body uses stored fat for energy. The drugs mimic a natural hormone known as glucagon-like peptide-1, which signals fullness to the brain after a meal. Because of this mechanism, the medications are formally classified as GLP-1 receptor agonists. They also slow down the digestive process and stimulate insulin production to lower blood sugar levels, which explains their initial development for managing type 2 diabetes.

## Availability and Prescription Guidelines

National Health Service prescriptions for Wegovy are strictly controlled through specialized weight management clinics, while Mounjaro remains accessible through general practitioners only for the highest-risk patients. Patients seeking Wegovy on the public healthcare system typically require a body mass index of 30 or higher, classifying them as medically obese, alongside a weight-related health condition such as high blood pressure. Furthermore, individuals are expected to have attempted diet and exercise interventions prior to receiving pharmaceutical assistance.

Mounjaro is available through public health practitioners for weight loss, but initial rollouts target a very restricted group of patients with a body mass index exceeding 40 and four concurrent weight-related health conditions. Private prescribers offer these treatments more broadly to adults who are classified as obese or overweight with an associated health risk. Private pharmacies have faced criticism for dispensing the medications too easily, prompting regulatory changes that mandate video calls or face-to-face consultations to verify patient size and health status.

## Potential Side Effects and Health Risks

Side effects associated with GLP-1 receptor agonists are common, though the majority tend to remain mild for most patients. Approximately half of all individuals taking these medications experience gastrointestinal issues, including nausea, bloating, acid reflux, constipation, and diarrhoea. Dr Sarah Jarvis, a general practitioner and clinical consultant at patient.info, explained that severe acute pancreatitis represents an uncommon but extremely painful adverse effect occurring in approximately one out of every 500 patients.

Additional uncommon complications include altered taste perceptions, kidney dysfunction, allergic reactions, gallbladder problems, and hypoglycemia. Clinical research examining whether these injections pose risks to patient mental health remains inconclusive. Scientists believe the drugs operate centrally within the brain to block signaling pathways associated with cravings for high-calorie items and guilty pleasures.

## Frequently asked questions

### Which alcoholic drink saw the biggest drop in sales among weight-loss jab users?

Sparkling wines such as champagne, prosecco, and cava experienced the largest decline, with a 27 percent drop in volume purchased.

### What did households using weight-loss medications buy more of?

Families with a weight-loss medication user increased their purchases of still wine, ready meals, fruit juice, water, yoghurt, and protein bars.


---

When citing, please link to https://briefzora.com/weight-loss-jabs-cut-sparkling-wine-sales-more-than-other-alcohol and name Briefzora as the source.
